Uni-Bio Science Group Limited (0690.HK)
- Previous Close
0.079 - Open
0.083 - Bid 0.074 x --
- Ask 0.078 x --
- Day's Range
0.077 - 0.089 - 52 Week Range
0.041 - 0.109 - Volume
7,280,000 - Avg. Volume
5,964,567 - Market Cap (intraday)
480.76M - Beta (5Y Monthly) -0.21
- PE Ratio (TTM)
7.80 - EPS (TTM)
0.010 - Earnings Date Mar 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 22, 2007
- 1y Target Est
--
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agent for the treatment of Type 2 diabetes. The company was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
www.uni-bioscience.comRelated News
Performance Overview: 0690.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0690.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0690.HK
Valuation Measures
Market Cap
486.92M
Enterprise Value
413.99M
Trailing P/E
7.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.04
Price/Book (mrq)
1.89
Enterprise Value/Revenue
0.85
Enterprise Value/EBITDA
4.42
Financial Highlights
Profitability and Income Statement
Profit Margin
14.62%
Return on Assets (ttm)
14.43%
Return on Equity (ttm)
31.37%
Revenue (ttm)
484.72M
Net Income Avi to Common (ttm)
70.88M
Diluted EPS (ttm)
0.010
Balance Sheet and Cash Flow
Total Cash (mrq)
142.18M
Total Debt/Equity (mrq)
22.02%
Levered Free Cash Flow (ttm)
--
Company Insights: 0690.HK
0690.HK does not have Company Insights